Active, not recruitingPhase 3NCT05248646
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Intervention
- Sibeprenlimab 400 mg(drug)
- Enrollment
- 530 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- University of Alabama at Birmingham - Site #336, Birmingham, Alabama, United States
- Mayo Clinic Arizona - Site #363, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences - Site #353, Little Rock, Arkansas, United States
- Amicis Research Center - Site #341, Granada Hills, California, United States
- University of CA San Diego - Site #351, La Jolla, California, United States
- California Institute of Renal Research - Site #371, La Mesa, California, United States
- Loma Linda University Health Care Clinical Trial Center Clinic - Site #372, Loma Linda, California, United States
- Academic Medical Research Institute - Site #333, Los Angeles, California, United States
- Kaiser Permanente - Southern California Permanente Medical Group SCPMG - LAMC - Site #325, Los Angeles, California, United States
- Stanford University - Site #370, Palo Alto, California, United States
- North America Research Institute - Site #335, San Dimas, California, United States
- University of California, San Francisco - Site #377, San Francisco, California, United States
- Colorado Kidney Care PC - Site #330, Denver, Colorado, United States
- Mayo Clinic in Florida - Site #321, Jacksonville, Florida, United States
- South Florida Research Institute - Site #323, Lauderdale Lakes, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05248646 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital